+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management

Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management

Archives of Internal Medicine 171(7): 657-667

Early, aggressive treatment of rheumatoid arthritis (RA) improves outcomes but confers increased risk. Risk stratification to target aggressive treatment of high-risk individuals with early RA is considered important to optimize outcomes while minimizing clinical and monetary costs. Some advocate the addition of magnetic resonance imaging (MRI) to standard RA risk stratification with clinical markers for patients early in the disease course. Our objective was to determine the incremental cost-effectiveness of adding MRI to standard risk stratification in early RA. Using a decision analysis model of standard risk stratification with or without MRI, followed by escalated standard treatment protocols based on treatment response, we estimated 1-year and lifetime quality-adjusted life-years, RA-related costs, and incremental cost-effectiveness ratios (with MRI vs without MRI) for RA patients with fewer than 12 months of disease and no baseline radiographic erosions. Inputs were derived from the published literature. We assumed a societal perspective with 3.0% discounting. One-year and lifetime incremental cost-effectiveness ratios for adding MRI to standard testing were $204,103 and $167,783 per quality-adjusted life-year gained, respectively. In 1-way sensitivity analyses, model results were insensitive to plausible ranges for every variable except MRI specificity, which published data suggest is below the threshold for MRI cost-effectiveness. In probabilistic sensitivity analyses, most simulations produced lifetime incremental cost-effectiveness ratios in excess of $100,000 per quality-adjusted life-year gained, a commonly cited threshold. Under plausible clinical conditions, adding MRI is not cost-effective compared with standard risk stratification in early-RA patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052370054

Download citation: RISBibTeXText

PMID: 21482840

DOI: 10.1001/archinternmed.2011.115

Related references

Cost effectiveness of adding magnetic resonance imaging to the usual management of suspected scaphoid fractures. British Journal of Sports Medicine 39(2): 75-79, 2005

The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. Arthritis and Rheumatism 52(8): 2300-2306, 2005

Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Annals of the Rheumatic Diseases 65(9): 1208-1212, 2006

Magnetic resonance imaging applications in early rheumatoid arthritis diagnosis and management. Rheumatic Diseases Clinics of North America 38(2): 277-297, 2012

Computerized measurement of magnetic resonance imaging erosion volumes in patients with rheumatoid arthritis: a comparison with existing magnetic resonance imaging scoring systems and standard clinical outcome measures. Arthritis and Rheumatism 48(3): 614-624, 2003

Is there a role for extremity magnetic resonance imaging in routine clinical management of rheumatoid arthritis?. Journal of Rheumatology 31(4): 640-644, 2004

Confirmation of effectiveness of tocilizumab by ultrasonography and magnetic resonance imaging in biologic agent-naïve early-stage rheumatoid arthritis patients. Modern Rheumatology 25(6): 948-953, 2016

A retrospective analysis of low-field strength magnetic resonance imaging and the management of patients with rheumatoid arthritis. Current Medical Research and Opinion 23(5): 961-968, 2007

Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: A retrospective pilot study. Modern Rheumatology 27(6): 953-960, 2017

Contrast-enhanced magnetic resonance imaging positively impacts the management of some patients with rheumatoid arthritis or suspected RA. Journal of Clinical Rheumatology 18(1): 15-22, 2012

Reducing invasiveness, duration, and cost of magnetic resonance imaging in rheumatoid arthritis by omitting intravenous contrast injection -- Does it change the assessment of inflammatory and destructive joint changes by the OMERACT RAMRIS?. Journal of Rheumatology 36(8): 1806-1810, 2009

Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis and Rheumatism 47(6): 655-661, 2003

The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technology Assessment 17(20): Vii-Xix, 1-281, 2014

Evaluation of rheumatoid arthritis using a scoring system devised from magnetic resonance imaging of rheumatoid knees. Acta Medica Okayama 52(4): 211-224, 1998

Cost-benefit and cost-effectiveness analyses of magnetic resonance imaging. International Journal of Technology Assessment in Health Care 1(3): 537-550, 1984